S&P 500   2,998.41 (+1.09%)
DOW   27,036.26 (+0.93%)
QQQ   193.44 (+1.22%)
AAPL   235.72 (-0.06%)
MSFT   141.45 (+1.36%)
AMZN   1,759.37 (+1.32%)
NVDA   199.18 (+6.78%)
MU   46.42 (+3.48%)
GE   8.87 (+1.72%)
AMD   30.73 (+0.66%)
T   37.89 (+1.12%)
PRI   123.75 (+1.88%)
NFLX   284.71 (-0.29%)
BAC   29.90 (+2.61%)
DIS   130.07 (+0.29%)
S&P 500   2,998.41 (+1.09%)
DOW   27,036.26 (+0.93%)
QQQ   193.44 (+1.22%)
AAPL   235.72 (-0.06%)
MSFT   141.45 (+1.36%)
AMZN   1,759.37 (+1.32%)
NVDA   199.18 (+6.78%)
MU   46.42 (+3.48%)
GE   8.87 (+1.72%)
AMD   30.73 (+0.66%)
T   37.89 (+1.12%)
PRI   123.75 (+1.88%)
NFLX   284.71 (-0.29%)
BAC   29.90 (+2.61%)
DIS   130.07 (+0.29%)
Log in

Athenex Stock Price, News & Analysis (NASDAQ:ATNX)

$11.00
+0.17 (+1.57 %)
(As of 10/15/2019 12:22 PM ET)
Today's Range
$10.85
Now: $11.00
$11.25
50-Day Range
$10.78
MA: $13.37
$15.41
52-Week Range
$9.38
Now: $11.00
$21.11
Volume20,279 shs
Average Volume735,201 shs
Market Capitalization$850.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.21
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.10 million
Book Value$1.92 per share

Profitability

Net Income$-117,440,000.00
Net Margins-161.17%

Miscellaneous

Employees575
Market Cap$850.08 million
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.


Athenex (NASDAQ:ATNX) Frequently Asked Questions

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

How were Athenex's earnings last quarter?

Athenex Inc (NASDAQ:ATNX) issued its earnings results on Wednesday, August, 7th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.00. The company had revenue of $22.20 million for the quarter, compared to analyst estimates of $18.15 million. Athenex had a negative net margin of 161.17% and a negative return on equity of 85.39%. View Athenex's Earnings History.

When is Athenex's next earnings date?

Athenex is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Athenex.

What price target have analysts set for ATNX?

6 brokerages have issued 12-month price targets for Athenex's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Athenex's stock price to reach $23.83 in the next twelve months. This suggests a possible upside of 116.5% from the stock's current price. View Analyst Price Targets for Athenex.

What is the consensus analysts' recommendation for Athenex?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athenex.

Has Athenex been receiving favorable news coverage?

Headlines about ATNX stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Athenex earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Athenex.

Are investors shorting Athenex?

Athenex saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 9,040,000 shares, an increase of 24.3% from the August 30th total of 7,270,000 shares. Based on an average daily trading volume, of 669,400 shares, the short-interest ratio is presently 13.5 days. Approximately 15.5% of the shares of the company are sold short. View Athenex's Current Options Chain.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Who are Athenex's key executives?

Athenex's management team includes the folowing people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)
  • Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

Who are Athenex's major shareholders?

Athenex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Jaffetilchin Investment Partners LLC (0.24%). Company insiders that own Athenex stock include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo, Song-Yi Zhang, Stephanie A Davis and William Wei Zuo. View Institutional Ownership Trends for Athenex.

Which institutional investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Jaffetilchin Investment Partners LLC. Company insiders that have sold Athenex company stock in the last year include Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Insider Buying and Selling for Athenex.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $11.01.

How big of a company is Athenex?

Athenex has a market capitalization of $850.85 million and generates $89.10 million in revenue each year. The company earns $-117,440,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Athenex employs 575 workers across the globe.View Additional Information About Athenex.

What is Athenex's official website?

The official website for Athenex is http://www.athenex.com/.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.


MarketBeat Community Rating for Athenex (NASDAQ ATNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Equity Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel